Business Development & Valorization
Accelerating Innovation in Regenerative Medicine
-
At RegMed XB, we turn cutting-edge research, enabling technologies, and novel therapies into viable businesses. Through strategic partnerships with established companies and high-potential start-ups, we help bring regenerative medicine innovations to patients faster.
Accelerating Life Sciences & Health Innovations
The Thematic Tech Transfer (TTT) programme: “Scaling Impact/Impact opschalen”, an initiative by RegMed XB and Dutch CardioVascular Alliance (DCVA), supports academic researchers in accelerating promising health innovations for chronic diseases towards societal and clinical impact through viable startup building to take the next step towards the patient. The programme is carried out in collaboration with the Dutch Diabetes Foundation, Dutch Heart Foundation, Dutch Brain Foundation and Dutch Kidney Foundation.
The TTT programme was established to bridge the gap between academic research and commercial application through new start-up formation. The programme supports groundbreaking academic researchers in advancing academic projects to investible propositions with the aim of accelerating the translation of academic innovations from the lab to the patient. Furthermore, the FIRST-II fund directly supports startups in the field of chronic diseases.
A key component of the programme is the pre-seed investment fund Fonds InvesteringsRijpe Starters-II (FIRST-II), managed by BioGeneration Ventures (BGV). FIRST-II invests in early-stage, research-driven startups, supporting their growth and preparing them for larger follow-on investments at a later stage.
The “Scaling Impact” programme builds on the success of the previous TTT scheme “Accelerating Impact”, in which DCVA and RegMed XB collaborated for five years, with FIRST as a central element.
A total of €10 million has been awarded to “Scaling Impact” by the Netherlands Enterprise Agency (RVO) on behalf of the Ministry of Economic Affairs and Climate Policy (EZK). This funding supports the entire TTT programme, including valorization vouchers and the further development of FIRST-II as a pre-seed investment fund for startups.
We bring science and entrepreneurship together by:
- Organizing (Valorization) Community events
- Educating researchers and policy makers
- Supporting researchers with valorization and expertise in vouchers
Our Impact Officers actively scout for high-impact research with start-up potential in the field of chronic diseases and guide research teams through the world of technology transfer and academic entrepreneurship.
-
Our Valorization Services include:
- Strategic and business development advice
- Access to a strong innovation and industry network
- Financial support through expertise in vouchers
- Guidance on start-up creation and market validation
We help innovators at every step — from evaluating early business ideas to bringing regenerative medicine solutions to the market.
Email for more information.
What researchers gain through TTT:
- Expert scientific, entrepreneurial, and strategic guidance
- Support to assess the clinical, societal, and commercial potential of innovations
- Preparation for next development steps, including making projects investment-ready
Why Work with RegMed XB?
- Deep expertise in regenerative medicine commercialization
- Established network across academia, industry, and clinical partners
- Proven track record in accelerating start-ups
- Strong national partnerships through TTT and DCVA
We empower innovators to turn breakthrough science into therapies, technologies, and businesses that deliver real impact.
-
Examples of entrepreneurial teams RegMed XB helped:
From serendipity to startup: the story behind SBMatrices
What began as an accidental discovery in a chemistry lab has evolved into a deeptech venture with the potential to significantly impact organoid research and regenerative medicine.
read more
XS Innovations bringing a new standard to dialysis care
XS Innovations is tackling a major challenge for people with end-stage kidney disease: keeping their blood vessel access open for dialysis. Most patients need a special connection between an artery and a vein in their arm, called an arteriovenous fistula (AVF), to ensure enough blood flows during treatment.
read more
Hello R&D sets out to eliminate liver toxicity
Liver toxicity is the number one reason for drugs to be retracted from the market. More reliable methods for predicting drug- induced liver toxicity will not only save drug development costs by detecting liver toxic drugs earlier, but will also spare patients from potential severe side effects due to liver toxicity.
read more
Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies
Phlox Therapeutics, is developing RNA-based therapies for genetic cardiomyopathies. Founded by Prof. Dr. Eva van Rooij and Prof. Dr. Yigal Pinto in 2022, the company has made significant progress with Dr. Margien Boels, PhD, as Chief Operating Officer.
read more -
Contact one of our Impact Officers
